Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 27, 2023

SELL
$87.74 - $117.27 $333,061 - $445,156
-3,796 Reduced 25.93%
10,841 $1.05 Million
Q4 2022

Jan 23, 2023

BUY
$80.93 - $108.63 $182,578 - $245,069
2,256 Added 18.22%
14,637 $0
Q3 2022

Oct 17, 2022

BUY
$82.16 - $96.94 $165,881 - $195,721
2,019 Added 19.48%
12,381 $1.09 Million
Q2 2022

Jul 26, 2022

BUY
$71.48 - $86.85 $740,675 - $899,939
10,362 New
10,362 $902,000
Q3 2020

Oct 15, 2020

SELL
$71.87 - $131.03 $545,133 - $993,862
-7,585 Closed
0 $0
Q2 2020

Jul 28, 2020

SELL
$79.55 - $124.22 $63,083 - $98,506
-793 Reduced 9.47%
7,585 $936,000
Q1 2020

Apr 13, 2020

BUY
$71.37 - $96.85 $597,937 - $811,409
8,378 New
8,378 $708,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Roman Butler Fullerton & CO Portfolio

Follow Roman Butler Fullerton & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Roman Butler Fullerton & CO, based on Form 13F filings with the SEC.

News

Stay updated on Roman Butler Fullerton & CO with notifications on news.